Drugs / Ad5-CoV5T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05886790 | May → Dec 2023 | COVID-19 | Zhongnan Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-CoV5T | “450 participants were enrolled and randomly assigned into three groups to be vaccinated with an aerosolized Ad5-vectored bivalent vaccine (wild-type and BA.5, Ad5-CoV5T), an...” PMID 40775215 ↗ Aug 2025 |
| Modality | Vaccine | “an aerosolized Ad5-vectored bivalent vaccine (wild-type and BA.5, Ad5-CoV5T)” PMID 40775215 ↗ Aug 2025 |
| Route | Inhaled | “receive one dose of inhaled prototype strain and omicron BA.4/5 bivalent recombinant SARS-CoV-2 vaccine (adenovirus vector type 5) (Ad5-NCO5T-IH)” NCT05886790 ↗ |